Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Liver International : Official Journal of the International Association for the Study of the Liver|July 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCCKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 10, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus BevacizumabKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 26, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus TremelimumabTomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabFujimasa Tada, Atsushi Hiraoka, Hideko Ohama, et al.
Hepatology (Baltimore, Md.)|May 6, 2026
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world studyKaho Aoe, Toshifumi Tada, Atsushi Hiraoka, et al.
Oncology|August 3, 2026
Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus BevacizumabEmi Tanaka, Toshifumi Tada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 9, 2026
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World StudyHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Liver Cancer|June 3, 2026
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
JHEP Reports : Innovation in Hepatology|April 25, 2025
Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survivalVincenzo Ronca, Alessandro Parente, Ellina Lytvyak, et al.
Pageof 14